Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. appears in FDA public data with 2 recalls, 0 510(k) clearances, 0 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0219-2019, Class III) was initiated on October 5, 2018.
Summary
- Total Recalls
- 2
- 510(k) Clearances
- 0
- Inspections
- 0
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0219-2019 | Class III | Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, | October 5, 2018 |
| D-1099-2018 | Class III | Contrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, | August 9, 2018 |